Strong earnings beat with adjusted net income more than tripling versus expectations, significant upward revision of full-year revenue guidance ($490-500M vs prior $447-465M), and EBITDA guidance increase ($66-78M vs prior $43-57M). CMS coverage affirmation and continued demand for transplant monitoring tests support positive momentum.
CareDx is divesting a lower-growth unit to focus on higher-growth core businesses (Testing Services +48%, Patient and Digital Solutions +33%). The $170 million proceeds support future acquisitions and growth initiatives. Strong Q1 revenue growth of 39% year-over-year and significant stock price appreciation of 28.54% indicate positive market reception of the strategic shift.
Articles that tag CDNA but are mainly about other companies.
Expected to deliver over 100% earnings growth this year with 35.2% improvement in consensus estimates over 60 days. Holds Zacks Rank #1 (Strong Buy) rating.
Expected earnings growth exceeding 100% with consensus estimates up 35.2% in 60 days. Zacks Rank #1 (Strong Buy) rating. Recommended as defensive healthcare pick.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
